Skip to main content
三元基因 logo

三元基因 — Investor Relations & Filings

Ticker · 920344 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2024-02-04 Board/Management Inform…
Country CN China
Listing Beijing Stock Exchange 920344

About 三元基因

http://www.triprime.com/

Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. is a biotechnology enterprise specializing in the research, development, production, and commercialization of modern genetic engineering pharmaceuticals. The company's core focus is on recombinant human interferon products, most notably Interferon ̑1b. This product is widely utilized in the treatment of viral diseases and malignant tumors, with a significant presence in the pediatric respiratory and hepatology markets. Tri-Prime Gene leverages advanced molecular biology and protein purification technologies to maintain its position as a leader in the interferon market. Its portfolio includes various formulations such as injections, sprays, and drops, designed to meet diverse clinical needs. The company continues to invest in innovative biopharmaceuticals, aiming to provide effective therapeutic solutions for infectious diseases and oncology.

Recent filings

Filing Released Lang Actions
关于调整第三届董事会审计委员会委员的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the adjustment of members of the company's third board audit committee. It references compliance with regulatory rules about independent directors and audit committee composition. The content focuses on changes in board committee membership rather than financial results or reports. The document length is short (925 characters) and it is clearly an announcement of a board/management change. Therefore, it fits the category of Board/Management Information (MANG).
2024-02-04 Chinese
关于变更持续督导保荐代表人的公告
Board/Management Information Classification · 95% confidence The document is an announcement regarding the change of the continuous supervision sponsor representative for Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the replacement of one sponsor representative with another due to personal work changes. The document is short (700 characters) and focuses on management changes related to sponsorship and supervision roles, not financial results or reports. This fits the category of Board/Management Information (MANG), which covers announcements of changes in company board or senior management roles. There is no indication of financial data, report publication, or voting results.
2024-02-04 Chinese
第三届董事会第十五次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of resolutions passed at a board meeting of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items including credit facility applications and board committee nominations, and voting results. There is no financial data or report content, only management and board decisions. This fits the category of Board/Management Information (MANG), which covers announcements of changes in the company's board or senior management and related board resolutions. The document length is short and it is not an annual or interim report, nor an earnings release or regulatory filing. Therefore, the classification is MANG with high confidence.
2024-02-04 Chinese
关于北京三元基因药业股份有限公司2024年第一次临时股东大会之法律意见书
Regulatory Filings
2024-01-03 Chinese
2024年第一次临时股东大会决议公告
Board/Management Information Classification · 100% confidence The document is a detailed announcement of the resolutions passed at the 2024 first extraordinary shareholders meeting of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It includes information about the meeting's convening, attendance, voting results on board member nominations, legal opinions on the meeting's validity, and the effective date of board and management changes. The content focuses on changes in the company's board of directors and senior management, specifically the appointment of independent and non-independent directors. There is no financial data, earnings information, or report publication notice. The document is not a full annual or interim report, nor is it a proxy solicitation or voting results announcement in isolation. It is a management/board information announcement about changes in the company's board and senior management. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is under 5,000 characters but contains substantive content about management changes, not just a brief announcement or report publication notice.
2024-01-03 Chinese
关于召开2024年第一次临时股东大会通知公告（提供网络投票）
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a notice announcing the convening of the 2024 first extraordinary general meeting of shareholders (临时股东大会) for Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the meeting date, voting methods, attendees, agenda items including board member nominations, and registration procedures. It does not contain financial statements or results, nor is it a transcript or report of the meeting. It is a formal announcement of a shareholders meeting, specifically an extraordinary general meeting (EGM). According to the filing definitions, announcements of shareholder meetings and related materials fall under the category of Proxy Solicitation & Information Statement (PSI). The document is under 5,000 characters and is not a report publication announcement or regulatory filing. Therefore, the best classification is PSI.
2023-12-14 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.